RecruitingPhase 2NCT06257537

Sustained Acoustic Medicine for Symptomatic Treatment of Knee Pain Related to Osteoarthritis


Sponsor

ZetrOZ, Inc.

Enrollment

300 participants

Start Date

Oct 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The purpose of this study is to assess the ability of long-duration low intensity therapeutic ultrasound (LITUS) to alleviate knee Osteoarthritis pain over a 24-week period. The primary objective of this study is to evaluate the analgesic effect of LITUS in subjects suffering from knee Osteoarthritis pain. Secondary objectives are to assess the ability of LITUS to improve joint function.


Eligibility

Min Age: 50 YearsMax Age: 85 Years

Inclusion Criteria10

  • Have physician-diagnosed mild to moderate knee OA (OARSI atlas grades 1-2)
  • Fulfill the American College of Rheumatology clinical and radiological diagnostic criteria for knee OA
  • Are between 50-85 years of age
  • Report a frequent pain score between 4-7 (range: 0-10) during the week preceding enrollment
  • Report that knee pain negatively affects quality of life
  • Are willing not to use any cream, gel, or topical solution during the administration of treatment other than the approved ultrasound gel provided to the subject at the initiation of the study
  • Are deemed appropriate by their physician or by the study site physician to participate.
  • Be willing and able to self-administer treatment daily within their place of residence or during normal daily activity, excluding bathing, showering, or other water activities which may result in submersion of the study device.
  • Not use or initiate use of opioid and/or non-opioid analgesic medications.
  • Be willing to discontinue any other interventional treatment modalities on the knee during the study period (e.g., transcutaneous electrical nerve stimulation, electronic muscle stimulation, traditional ultrasound).

Exclusion Criteria16

  • Cannot successfully demonstrate the ability to put on and take off the device.
  • Displays any condition which, in the judgment of the investigator, would make participation in the study unacceptable including, but not limited to, the subject's ability to understand and follow instructions.
  • Participated in a clinical trial for an investigational drug and/or agent within 30 days prior to screening.
  • Is pregnant.
  • Is a prisoner.
  • Is non-ambulatory (unable to walk).
  • Has a pacemaker.
  • Has a malignancy in the treatment area.
  • Has an active infection, open sores, or wounds in the treatment area.
  • Has impaired sensation in the treatment area, such as caused by chemotherapy or anesthesia.
  • Has a known neuropathy (disease of the brain or spinal nerves).
  • Has a hereditary disposition (tendency) for excessive bleeding (hemorrhage).
  • Have knee replacement, other surgical intervention, or hyaluronidase injection in the affected knee in the past 6 months.
  • Are currently taking steroids.
  • Have any contraindication to radiograph.
  • Have a secondary cause of arthritis (metabolic or inflammatory).

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICESustained Acoustic Device with 2.5% Diclofenac Patch

Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours of continuous therapeutic ultrasound at 3 megahertz(MHz) frequency and 0.132 Watts/cm\^2 with 2.5% Diclofenac patches.

DEVICESustained Acoustic Device with 0% Diclofenac Patch

Patients apply the SAM Ultrasonic Diathermy Device daily for 1-4 hours with 0% diclofenac patches.

DRUG2.5% Diclofenac Patches

Topical pain relief-gel worn for 4 hours at least 5 days a week via SAM patch.

OTHERSAM Patch

Ultrasound gel without additional pain relief medication worn for 4 hours at least 5 days a week via SAM patch.


Locations(3)

Orthopaedic Foundation

Stamford, Connecticut, United States

ZetrOZ Systems

Trumbull, Connecticut, United States

Cayuga Medical Center - Medical Pain Consultants

Dryden, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06257537


Related Trials